IDEAYA Biosciences, Inc. — fact timeline

IDEAYA Biosciences, Inc. reported financial results for the first quarter ended March 31, 2026.

“On May 5, 2026, IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2026.”

IDEAYA Biosciences, Inc. terminated Collaboration, Option and License Agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited (effective 2025-12-09).

“On December 9, 2025, GlaxoSmithKline Intellectual Property (No. 4) Limited ("GSK") delivered written notice to IDEAYA Biosciences, Inc. (the "Company") of its election to terminate the Collaboration, Option and License Agreement, dated June 15, 2020 (as amended, the "Agreement").”

Susan L. Kelley, M.D. resigned as Director at IDEAYA Biosciences, Inc..

“Dr. Kelley will resign from the Board at the end of her current term, which will conclude immediately after the Annual Meeting.”

Joshua Bleharski was appointed as Chief Financial Officer at IDEAYA Biosciences, Inc..

“On February 10, 2025, the Board of Directors (the “Board”) of IDEAYA Biosciences, Inc. (the “Company”) appointed Joshua Bleharski, Ph.D. as Chief Financial Officer of the Company, effective early May 2025”

Jason Throne resigned as Chief Legal Officer and Secretary at IDEAYA Biosciences, Inc..

“On June 21, 2024, Jason Throne informed IDEAYA Biosciences, Inc. (the “Company”) of his voluntary resignation from his positions as Chief Legal Officer and Secretary of the Company.”

IDEAYA Biosciences, Inc. reported financial results for first quarter ended March 31, 2024.

“On May 7, 2024, IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2024.”

IDEAYA Biosciences, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.

“On February 20, 2024, IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2023.”

IDEAYA Biosciences, Inc. entered into Open Market Sales Agreement with Jefferies LLC valued at up to $350,000,000 (effective 2024-01-19).

“On January 19, 2024, IDEAYA Biosciences, Inc. (the “Company”) entered into an Open Market Sales Agreement (the “Sales Agreement”) with Jefferies LLC (“Jefferies”), with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”), having aggregate gross proceeds of up to $350.0 million (the “Shares”) through Jefferies as its sales agent.”

IDEAYA Biosciences, Inc. entered into Office Lease Agreement with AAT TORREY 13-14, LLC valued at $1,581,469 (effective 2023-11-14).

“On November 14, 2023, IDEAYA Biosciences, Inc. (the “Company”) entered into an Office Lease Agreement (the “Lease”), dated November 14, 2023, with AAT TORREY 13-14, LLC (“Landlord”).”

IDEAYA Biosciences, Inc. reported financial results for third quarter ended September 30, 2023.

“announced its financial results for the third quarter ended September 30, 2023”

Paul A. Stone resigned as Chief Financial Officer at IDEAYA Biosciences, Inc..

“On September 21, 2023, Paul A. Stone informed IDEAYA Biosciences, Inc. (the “Company”), of his voluntary resignation from his position as Chief Financial Officer of the Company. Mr. Stone’s resignation will be effective as of November 10, 2023”

IDEAYA Biosciences, Inc. reported financial results for the second quarter ended June 30, 2023.

“IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the second quarter ended June 30, 2023.”

Andres Ruiz Briseno was appointed as Principal Accounting Officer at IDEAYA Biosciences, Inc..

“appointed Andres Ruiz Briseno as Principal Accounting Officer of the Company, effective July 1, 2023”

IDEAYA Biosciences, Inc. shareholders approved Ratification of the selection, by the Audit Committee of the Board of Directors of the Company, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2023 at the 2023-06-07 meeting.

“Proposal 2 . The ratification of the selection, by the Audit Committee of the Board of Directors of the Company, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2023: Votes For Votes Against Abstentions 44,628,878 49,514 999”

IDEAYA Biosciences, Inc. shareholders approved Election of three Class I directors to hold office until the 2026 annual meeting of stockholders or until their respective successors are elected at the 2023-06-07 meeting.

“Proposal 1. The election of three Class I directors to hold office until the 2026 annual meeting of stockholders or until their respective successors are elected: Nominee Votes For Votes Withheld Broker Non-Votes Yujiro S. Hata 41,311,283 1,117,424 2,250,384 M. Garret Hampton, Ph.D. 36,443,001 5,985,706 2,250,384 Catherine J. Mackey, Ph.D. 40,989,747 1,438,960 2,250,384”

IDEAYA Biosciences, Inc. entered into Lease with DW LSP 5000 Shoreline, LLC valued at thirty-six million seven hundred sixty-five thousand seven hundred seventy-seven dollars in U.S. dol (effective 2023-06-01).

“On June 1, 2023, IDEAYA Biosciences, Inc. (the “Company”) entered into a Lease (the “Lease”), dated June 1, 2023, with DW LSP 5000 Shoreline, LLC (“Landlord”).”

IDEAYA Biosciences, Inc. terminated Clinical Trial Collaboration and Supply Agreement with Pfizer Inc. valued at terminates the Clinical Trial Collaboration and Supply Agreement dated March 9, 2022 (the “Third Pfi (effective 2023-05-12).

“Amendment No. 1 additionally terminates the Clinical Trial Collaboration and Supply Agreement dated March 9, 2022 (the “Third Pfizer Agreement”) between the Company and Pfizer relating to Pfizer’s supply of crizotinib in support of the Company’s potential Phase 1 clinical trial to evaluate darovasertib in combination with crizotinib in cMET driven tumors such as non-small cell lung cancer and/or hepatocellular carcinoma.”

IDEAYA Biosciences, Inc. amended Clinical Trial Collaboration and Supply Agreement with Pfizer Inc. valued at increase the defined quantity of crizotinib provided by Pfizer to the Company at no cost and to defi (effective 2023-05-12).

“On May 16, 2023, IDEAYA Biosciences, Inc. (the “Company”) announced that on May 12, 2023 it had entered into an Amendment No. 4 (“Amendment No. 4”) to the Clinical Trial Collaboration and Supply Agreement dated March 11, 2020 (the “Pfizer Agreement”) between the Company and Pfizer Inc. (“Pfizer”) relating to Pfizer’s supply of its investigational cMET inhibitor, crizotinib, in support of the Company’s ongoing Phase 1/2 clinical trial evaluating the Company’s investigational small molecule protein kinase C, or PKC, inhibitor darovasertib in combination with crizotinib in metastatic uveal melanoma, or MUM, patients.”

IDEAYA Biosciences, Inc. reported financial results for the first quarter ended March 31, 2023.

“On May 9, 2023, IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.”

IDEAYA Biosciences, Inc. reported financial results for year ended December 31, 2022.

“On March 7, 2023, IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2022.”

IDEAYA Biosciences, Inc. reported financial results for the third quarter ended September 30, 2022.

“On November 8, 2022, IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2022.”

Catherine J. Mackey was appointed as member of the Board of Directors at IDEAYA Biosciences, Inc..

“On April 6, 2022, IDEAYA Biosciences, Inc. (the “Company”) announced the appointment of Catherine J. Mackey, Ph.D. as a member of its Board of Directors (the “Board”), effective April 5, 2022.”